JP6434650B2 - 糖尿病創傷治療用イソキノリン誘導体の新規使用 - Google Patents
糖尿病創傷治療用イソキノリン誘導体の新規使用 Download PDFInfo
- Publication number
- JP6434650B2 JP6434650B2 JP2017549520A JP2017549520A JP6434650B2 JP 6434650 B2 JP6434650 B2 JP 6434650B2 JP 2017549520 A JP2017549520 A JP 2017549520A JP 2017549520 A JP2017549520 A JP 2017549520A JP 6434650 B2 JP6434650 B2 JP 6434650B2
- Authority
- JP
- Japan
- Prior art keywords
- salsolinol
- treatment
- rats
- wounds
- diabetic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010012601 diabetes mellitus Diseases 0.000 title claims description 33
- 208000027418 Wounds and injury Diseases 0.000 title claims description 31
- 206010052428 Wound Diseases 0.000 title claims description 30
- 125000002183 isoquinolinyl group Chemical class C1(=NC=CC2=CC=CC=C12)* 0.000 title description 7
- IBRKLUSXDYATLG-LURJTMIESA-N (S)-salsolinol Chemical compound OC1=C(O)C=C2[C@H](C)NCCC2=C1 IBRKLUSXDYATLG-LURJTMIESA-N 0.000 claims description 30
- 229940074569 salsolinol Drugs 0.000 claims description 29
- IBRKLUSXDYATLG-UHFFFAOYSA-N salsolinol hydrobromide Natural products OC1=C(O)C=C2C(C)NCCC2=C1 IBRKLUSXDYATLG-UHFFFAOYSA-N 0.000 claims description 29
- 239000003814 drug Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 241000700159 Rattus Species 0.000 description 24
- 125000000217 alkyl group Chemical group 0.000 description 13
- 150000001875 compounds Chemical class 0.000 description 12
- 238000011084 recovery Methods 0.000 description 8
- BHLYRWXGMIUIHG-HNNXBMFYSA-N (S)-reticuline Chemical compound C1=C(O)C(OC)=CC=C1C[C@H]1C2=CC(O)=C(OC)C=C2CCN1C BHLYRWXGMIUIHG-HNNXBMFYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 230000029663 wound healing Effects 0.000 description 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- RUPUUZZJJXCDHS-UHFFFAOYSA-N (+)-orientaline Natural products C1=C(O)C(OC)=CC(CC2C3=CC(O)=C(OC)C=C3CCN2C)=C1 RUPUUZZJJXCDHS-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- WYQVAPGDARQUBT-FGWHUCSPSA-N Madecassol Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O)OC[C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)OC(=O)[C@]12CC[C@H]([C@@H]([C@H]1C=1[C@@]([C@@]3(CC[C@H]4[C@](C)(CO)[C@@H](O)[C@H](O)C[C@]4(C)[C@H]3CC=1)C)(C)CC2)C)C)[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O WYQVAPGDARQUBT-FGWHUCSPSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- WYQVAPGDARQUBT-XCWYDTOWSA-N asiaticoside Natural products O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@H](O)[C@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)[C@@H](CO)O2)O1)[C@@]12[C@@H]([C@@H](C)[C@H](C)CC1)C=1[C@](C)([C@@]3(C)[C@@H]([C@@]4(C)[C@H]([C@@](CO)(C)[C@@H](O)[C@H](O)C4)CC3)CC=1)CC2 WYQVAPGDARQUBT-XCWYDTOWSA-N 0.000 description 3
- 229940022757 asiaticoside Drugs 0.000 description 3
- QCYLIQBVLZBPNK-UHFFFAOYSA-N asiaticoside A Natural products O1C(C(=O)C(C)C)=CC(C)C(C2(C(OC(C)=O)CC34C5)C)C1CC2(C)C3CCC(C1(C)C)C45CCC1OC1OCC(O)C(O)C1O QCYLIQBVLZBPNK-UHFFFAOYSA-N 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- BNUZUOWRDKPBQR-UHFFFAOYSA-N reticuline Natural products CN1CCC2=CC(OC)=CC=C2C1CC1=CC=C(OC)C(O)=C1 BNUZUOWRDKPBQR-UHFFFAOYSA-N 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- 244000146462 Centella asiatica Species 0.000 description 2
- 235000004032 Centella asiatica Nutrition 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 125000004423 acyloxy group Chemical group 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 240000001548 Camellia japonica Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000005764 Peripheral Arterial Disease Diseases 0.000 description 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 1
- 229920000153 Povidone-iodine Polymers 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 235000018597 common camellia Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- -1 nitrogen-containing organic compounds Chemical class 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229960001621 povidone-iodine Drugs 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
を有する化合物とを含む医薬組成物を、それを必要とする対象に投与することを含む、糖尿病創傷を治療する方法を提供する。
を有する。
を有する化合物とを含む医薬組成物を、それを必要とする対象に投与することを含む。
を有する。
ドーパミン(1.6g)、10mLのメタノール、1mLの1N塩酸、および2mLの99%アセトアルデヒドを50mLの丸底フラスコに連続して加え、室温下で6時間撹拌した。減圧濃縮によって得られた濃縮物をLobar RP−18カラム(サイズB、Merck)に充填し、0.05%のギ酸水溶液によって溶出して、1H NMRにより本質的に純粋なサルソリノール(1.0g)を得た。
1H NMR(CD3OD,400MHz)δ6.63(1H,s),6.57(1H,s),4.30(1H,q,J=6.8Hz,H−1),3.40(1H,dt,J=12.6,5.6Hz,Ha−3),3.20(1H,ddd,J=12.6,8.2,5.6Hz,Hb−3),2.92(1H,ddd,J=16.8,8.2,5.8Hz,Ha−4),2.80(1H,dt,J=16.8,5.6Hz,Hb−4),1.55(3H,d,J=6.8Hz,Me−1);ESIMS:m/z180([M+H]+)。
0.01mg/g、0.03mg/g、0.1mg/g、および0.3mg/gにおけるサルソリノール軟膏を、それぞれ、0.5mg、1.5mg、5mg、および15mgのサルソリノールを、2.5mLのグリセロール(Sigma Inc.、MO、USA)プラス1.0mLのCreagel乳化剤(First Chemical、TPE、台湾)および45.5mLの蒸留水に溶解することによって調製した。ビヒクルは、グリセロール(2.5mL)、Creagel乳化剤(1.0mL)および蒸留水(45.5mL)から構成された。
Claims (1)
- サルソリノールの、糖尿病創傷を局所的に治療するための医薬を製造するための使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662291923P | 2016-02-05 | 2016-02-05 | |
US62/291,923 | 2016-02-05 | ||
PCT/CN2016/083642 WO2017133146A1 (en) | 2016-02-05 | 2016-05-27 | New use of isoquinoline derivatives for diabetic wound healing |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2018518453A JP2018518453A (ja) | 2018-07-12 |
JP6434650B2 true JP6434650B2 (ja) | 2018-12-05 |
Family
ID=58708466
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017549520A Active JP6434650B2 (ja) | 2016-02-05 | 2016-05-27 | 糖尿病創傷治療用イソキノリン誘導体の新規使用 |
Country Status (9)
Country | Link |
---|---|
US (1) | US9655891B1 (ja) |
EP (1) | EP3265089B1 (ja) |
JP (1) | JP6434650B2 (ja) |
KR (1) | KR101955141B1 (ja) |
CN (1) | CN107427508B (ja) |
AU (1) | AU2016390920B2 (ja) |
CA (1) | CA2986941C (ja) |
TW (1) | TWI702952B (ja) |
WO (1) | WO2017133146A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201945000A (zh) * | 2018-01-22 | 2019-12-01 | 資元堂生物科技股份有限公司 | 異喹啉衍生物用於傷口癒合的新穎用途 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR910002456B1 (ko) * | 1988-08-30 | 1991-04-22 | 삼화기연 주식회사 | 전자식 전압 계전기 |
KR950005921B1 (ko) * | 1991-12-03 | 1995-06-07 | 주식회사미원 | 발효법에 의한 l-글루타민산의 제조방법(i) |
US9051758B2 (en) * | 2013-07-19 | 2015-06-09 | The Boeing Company | Door snubber and strike plate |
CN105078992B (zh) * | 2014-05-23 | 2017-11-21 | 资元堂生物科技股份有限公司 | 异喹啉生物碱衍生物用于制备促进ampk活性的药物的用途 |
TWI621438B (zh) * | 2014-05-23 | 2018-04-21 | 資元堂生物科技股份有限公司 | 異喹啉生物鹼衍生物用於製備促進ampk活性的藥物之用途 |
-
2016
- 2016-05-27 WO PCT/CN2016/083642 patent/WO2017133146A1/en active Application Filing
- 2016-05-27 CA CA2986941A patent/CA2986941C/en active Active
- 2016-05-27 AU AU2016390920A patent/AU2016390920B2/en active Active
- 2016-05-27 US US15/166,964 patent/US9655891B1/en active Active
- 2016-05-27 CN CN201680015291.9A patent/CN107427508B/zh active Active
- 2016-05-27 EP EP16888967.3A patent/EP3265089B1/en active Active
- 2016-05-27 TW TW105116658A patent/TWI702952B/zh active
- 2016-05-27 KR KR1020177026203A patent/KR101955141B1/ko active IP Right Grant
- 2016-05-27 JP JP2017549520A patent/JP6434650B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
US9655891B1 (en) | 2017-05-23 |
CN107427508A (zh) | 2017-12-01 |
JP2018518453A (ja) | 2018-07-12 |
TWI702952B (zh) | 2020-09-01 |
EP3265089A1 (en) | 2018-01-10 |
KR101955141B1 (ko) | 2019-03-06 |
CA2986941A1 (en) | 2017-08-10 |
EP3265089A4 (en) | 2019-01-23 |
TW201728326A (zh) | 2017-08-16 |
EP3265089B1 (en) | 2021-04-28 |
CN107427508B (zh) | 2023-01-31 |
CA2986941C (en) | 2019-02-12 |
AU2016390920A1 (en) | 2018-03-15 |
KR20170110158A (ko) | 2017-10-10 |
WO2017133146A1 (en) | 2017-08-10 |
AU2016390920B2 (en) | 2018-10-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6929479B2 (ja) | 激越の治療のための舌下デクスメデトミジンの使用 | |
CN104981253B (zh) | 固溶体组合物及其在慢性炎症中的用途 | |
DK168514B1 (da) | Synergistisk produkt indeholdende en kombination af amantadin og selegilin, fremgangsmåde til fremstilling af produktet og anvendelse af amantadin og selegilin til fremstilling af produktet | |
WO2007122619A3 (en) | Tto-based wide spectrum therapeutics, disinfectants & anesthetics for use in aquaculture | |
EA201270144A1 (ru) | Комбинированная терапия при лечении диабета | |
US11352315B2 (en) | Compositions and methods comprising a triaryl polyamine | |
JP2017533972A5 (ja) | ||
RU2005135433A (ru) | Усилители всасывания, такие как внт, вна или пропилгаллат | |
JP2010535198A (ja) | コハク酸のコリン塩を含む鼻腔内投与用医薬品組成物 | |
US11938151B1 (en) | Method of making gold nanoparticles capped with Reseda arabica extract and treatment method using the same | |
JP6434650B2 (ja) | 糖尿病創傷治療用イソキノリン誘導体の新規使用 | |
RU2005135428A (ru) | Поглощение макромолекул | |
JP2006528246A5 (ja) | ||
WO2007139433A8 (en) | Peptide substance normalizing the metabolism in osseous and cartilaginous tissues, pharmaceutical composition on its base and the method of its application | |
US10376488B2 (en) | Use of flavonoids in manufacturing compositions for wound healing | |
US20190224187A1 (en) | New use of isoquinoline derivatives for wound healing | |
RU2005140739A (ru) | Применение альфа-кетоглутаровой кислоты для лечения недостаточности питания или состояния с высоким уровнем глюкозы в плазме | |
RU2005140156A (ru) | Применение аивлозина для лечения болезней, вызванных brachyspira pilosicoli или ornithobacterium rhinotracheale | |
EP2937084A1 (en) | Method for the treatment of hypercholesterolemia | |
US9192602B2 (en) | Indication of anthra[2,1,c][1,2,5]thiadiazole-6,11-dione compound in alleviating pain | |
CN104306436B (zh) | 一种快速止痒消毒制品 | |
CN117797155B (zh) | 对抗***毒性的药物制剂 | |
JPWO2020009950A5 (ja) | ||
JP2007518692A (ja) | ***不全治療方法 | |
CN1272012C (zh) | 一种治疗皮肤病的药物组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180620 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180703 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181001 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20181016 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20181108 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6434650 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |